 |
 |
Janet, Does this new drug have the same results in patients that have been on Sinemet for more than 11 years? Thanks , Sandy David and Sandy Norris "Faith is the daring of the soul to go farther than it can see." William Newton Clarke Sandy 38/dx'd for 11/had pd for 19yrs ----- Original Message ----- From: janet paterson <[log in to unmask]> To: <[log in to unmask]> Sent: Wednesday, May 05, 1999 7:27 AM Subject: PMID: 10223406: Pramipexole - a new dopamine agonist for PD > Pramipexole--a new dopamine agonist for the treatment of PD > > Although L-DOPA is the current 'gold standard' for treatment of Parkinson's > disease, its effectiveness fades rapidly [ed. note - 'huh?'] and its use > results in serious motor fluctuations (on-off, wearing off, freezing, > involuntary movements) for most patients with Parkinson's disease. > > Pramipexole is an aminothiazole dopamine agonist with selective actions at > dopamine receptors belonging to the D2 subfamily, where it possesses full > activity similar to dopamine itself. > > Pramipexole's preferential affinity for the D3 receptor subtype could > contribute to efficacy in the treatment of both the motor and psychiatric > symptoms of Parkinson's disease. > > Both in vitro and in vivo studies in animals suggest that pramipexole > possesses numerous neuroprotective properties, including dopamine > autoreceptor agonist properties, antioxidant properties, ability to block > the mitochondrial permeability transition pore and the ability to stimulate > the release of trophic factors. > > Clinical studies have demonstrated that pramipexole has excellent > pharmacokinetic properties and that it is an effective monotherapy in > treating early Parkinson's disease and an effective adjunctive therapy with > L-DOPA in treating late Parkinson's disease. > > In addition, pramipexole has demonstrated efficacy in a clinical trial for > the treatment of major depression. > > In the early disease studies, pramipexole was able to retard the need for > L-DOPA treatment for several years. > > Thus, a new 'L-DOPA-sparing' paradigm for treating Parkinson's disease may > now be possible, whereby patients are initially treated with pramipexole > and L-DOPA is added only as necessary. > > J Neurol Sci 1999 Feb 1;163(1):25-31 > Bennett JP Jr, Piercey MF > University of Virginia Health Sciences Center, Charlottesville VA 22908 > USA. <[log in to unmask] > > PMID: 10223406, UI: 99237917 > <http://www.ncbi.nlm.nih.gov/> > > janet paterson - 52 now /41 dx /37 onset - [log in to unmask] > 613/256/8340 - PO Box 171/Almonte/Ontario/K0A 1A0/Canada > > Scan some of My Past Posts at: > http://www.geocities.com/SoHo/Village/6263/ > Mine the PD List Archives at: > http://james.parkinsons.org.uk/ > Cull Nine Million Pub-Med Medical Studies at: > http://www.ncbi.nlm.nih.gov/PubMed/ > Comb the 'People With Parkinson's' PWP WebRing at: > http://www.webring.org/cgi-bin/webring?ring=parkie;list